Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

Paclitaxel 2liposomal doxorubicin 1EP-100 membrane-disrupting peptide 1Carboplatin 1AC 7700 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Ovarian Cancer Recurrent × Clear all
NCT06014528 2025-04-30

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 2 Recruiting
168 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01332656 2015-12-21

OPSALIN

Sanofi

Phase 2 Completed
154 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed
49 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡